pomalidomide has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ke, Y; Liang, JJ; Liu, HM; Shan, LH; Wang, N; Wang, YL; Wang, ZJ; Xie, H; Yang, RH; Zheng, ZJ; Zhou, C | 1 |
| Corral, LG; Fleming, YW; Stein, B; Zhu, D | 1 |
2 other study(ies) available for pomalidomide and Cancer of Prostate
| Article | Year |
|---|---|
Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Proteolysis; Receptors, Androgen; Structure-Activity Relationship | 2021 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Neoplasms; Prostatic Neoplasms; Thalidomide | 2008 |